Precision Neuromed
Precision NeuroMed is a clinical-stage CNS biotechnology company advancing a late-stage, clinically validated therapy for glioblastoma (GBM)—one of the deadliest human cancers with no meaningful improvement in survival for nearly two decades. Our lead program, PNM-201, an oncolytic protein designed to eliminate the tumor cell population responsible for recurrence and treatment resistance. In prior clinical studies, PNM-201 demonstrated extraordinary long-term survival outcomes (5–20+ years) in a subset of patients—results rarely seen in GBM. Subsequent analysis revealed a clear conclusion: the drug worked when it reached the right place in the brain at the right dose.
We have re-engineered the delivery of PNM-201 using a precision, brain-only delivery platform (convection enhanced delivery) that enables consistent, reproducible therapeutic exposure across the target region—unlocking the true potential of a proven drug asset while avoiding systemic toxicity.
Beyond GBM, our delivery platform creates a foundation for advancing additional CNS therapeutics that have historically failed due to delivery—not biology.
